Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation

Circulation Research

Volumn 108, Issue 6, 2011, Pages 676-685

  Leksa, Vladimir ^a   Loewe, Robert ^b,c   Binder, Brigitte ^a   Schiller, Herbert B ^a   Eckerstorfer, Paul ^a   Forster, Florian ^a   Soler Cardona, Ana ^c   Ondrovičová, Gabriela ^b   Kutejová, Eva ^b   Steinhuber, Eva ^a   Breuss, Johannes ^d   Drach, Johannes ^d   Petzelbauer, Peter ^c   Binder, Bernd R ^d   Stockinger, Hannes ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c Universitatsklinik fur Dermatologie   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

angiogenesis; cell migration; fibrinolysis; tumor invasion

Indexed keywords

MANNOSE 6 PHOSPHATE; PEPTIDE; PLASMINOGEN; SOMATOMEDIN B RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UROKINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER CELL; CELL INVASION; CELL SURFACE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RNA INTERFERENCE; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL;

ADAM PROTEINS; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CHIMERA; ENDOTHELIAL CELLS; GROWTH; HUMANS; MELANOMA; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMINOGEN; RECEPTOR, IGF TYPE 2; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SOLUBILITY; UMBILICAL VEINS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79953041116     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.234732     Document Type: Article

References (57)

1. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006; 26:716-728. (Pubitemid 43732143)
2. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34:122-136.
3. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol. 2002;192:160-170. (Pubitemid 34747784)
4. Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner PM, Stockinger H, Binder BR. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res. 2004;94:1562-1570. (Pubitemid 38856963)
5. Bastholm L, Nielsen MH, De Mey J, Dano K, Brunner N, Hoyer-Hansen G, Ronne E, Elling F. Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotech Histochem. 1994;69:61-67. (Pubitemid 24102343)
6. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 2008;14:5649-5655.
7. Leksa V, Godar S, Cebecauer M, Hilgert I, Breuss J, Weidle UH, Horejsi V, Binder BR, Stockinger H. The N terminus of mannose 6-phosphate/ insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration. J Biol Chem. 2002;277:40575-40582. (Pubitemid 35215637)
8. Schiller HB, Szekeres A, Binder BR, Stockinger H, Leksa V. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Mol Biol Cell. 2009;20: 745-756.
9. Bobek G, Scott CD, Baxter RC. Secretion of soluble insulin-like growth factor-II/mannose 6-phosphate receptor by rat tissues in culture. Endocrinology. 1991;128:2204-2206.
10. Confort C, Rochefort H, Vignon F. Insulin-like growth factors (IGFs) stimulate the release of alpha 1-antichymotrypsin and soluble IGF-II/ mannose 6-phosphate receptor from MCF7 breast cancer cells. Endocrinology. 1995;136:3759-3766.
11. Clairmont KB, Czech MP. Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J Biol Chem. 1991;266:12131-12134. (Pubitemid 21907066)
12. Scott CD, Baxter RC. Regulation of soluble insulin-like growth factor-II/mannose 6-phosphate receptor in hepatocytes from intact and regenerating rat liver. Endocrinology. 1996;137:3864-3870. (Pubitemid 26284658)
13. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, Stroher U, Klenk HD, Volchkov V. Ectodomain shedding of the glyco-protein GP of Ebola virus. EMBO J. 2004;23:2175-2184. (Pubitemid 38737744)
14. Kiess W, Greenstein LA, White RM, Lee L, Rechler MM, Nissley SP. Type II insulin-like growth factor receptor is present in rat serum. Proc Natl Acad Sci USA. 1987;84:7720-7724.
15. MacDonald RG, Tepper MA, Clairmont KB, Perregaux SB, Czech MP. Serum form of the rat insulin-like growth factor II/mannose 6-phosphate receptor is truncated in the carboxyl-terminal domain. J Biol Chem. 1989;264:3256-3261. (Pubitemid 19063383)
16. Costello M, Baxter RC, Scott CD. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 1999;84:611-617. (Pubitemid 29075693)
17. Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur J Immunol. 1999;29: 1004-1013. (Pubitemid 29119081)
18. Cederholm-Williams SA. Concentration of plasminogen and antiplasmin in plasma and serum. J Clin Pathol. 1981;34:979-981. (Pubitemid 11062203)
19. De Bleser PJ, Scott CD, Niki T, Xu G, Wisse E, Geerts A. Insulin-like growth factor II/mannose 6-phosphate-receptor expression in liver and serum during acute CCl4 intoxication in the rat. Hepatology. 1996;23:1530-1537. (Pubitemid 26181237)
20. Hattey E, Wojta J, Binder BR. Monoclonal antibodies against four different epitopes of plasminogen exhibit different effects on plasminogen activation kinetics. Thromb Haemost. 1987;58:440.
21. Bohnsack RN, Patel M, Olson LJ, Twining SS, Dahms NM. Residues essential for plasminogen binding by the cation-independent mannose 6-phosphate receptor. Biochemistry. 2010;49:635-644.
22. Leksa V, Godar S, Schiller HB, Fuertbauer E, Muhammad A, Slezakova K, Horejsi V, Steinlein P, Weidle UH, Binder BR, Stockinger H. TGF-{beta}-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J Cell Sci. 2005;118:4577-4586. (Pubitemid 41556353)
23. Olson LJ, Yammani RD, Dahms NM, Kim JJ. Structure of uPAR, plas-minogen, and sugar-binding sites of the 300 kDa mannose 6-phosphate receptor. EMBO J. 2004;23:2019-2028. (Pubitemid 38737729)
24. Bohnsack RN, Song X, Olson LJ, Kudo M, Gotschall RR, Canfield WM, Cummings RD, Smith DF, Dahms NM. Cation-independent mannose 6-phosphate receptor: a composite of distinct phosphomannosyl binding sites. J Biol Chem. 2009;284:35215-35226.
25. Dahms NM, Wick DA, Brzycki-Wessell MA. The bovine mannose 6-phosphate/insulin-like growth factor II receptor. Localization of the insulin-like growth factor II binding site to domains 5-11. J Biol Chem. 1994;269:3802-3809.
26. Garmroudi F, MacDonald RG. Localization of the insulin-like growth factor II (IGF-II) binding/cross-linking site of the IGF-II/mannose 6-phosphate receptor to extracellular repeats 10-11. J Biol Chem. 1994; 269:26944-26952.
27. Kang JX, Li Y, Leaf A. Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. Proc Natl Acad Sci USA. 1997;94:13671-13676. (Pubitemid 28009641)
28. Causin C, Waheed A, Braulke T, Junghans U, Maly P, Humbel RE, von Figura K. Mannose 6-phosphate/insulin-like growth factor II-binding proteins in human serum and urine. Their relation to the mannose 6-phosphate/insulin-like growth factor II receptor. Biochem J. 1988;252: 795-799.
29. Ellis V. Plasminogen activation at the cell surface. Curr Top Dev Biol. 2003;54:263-312. (Pubitemid 137639472)
30. Ellis V, Whawell SA, Werner F, Deadman JJ. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen. Biochemistry. 1999;38:651-659.
31. Stillfried GE, Saunders DN, Ranson M. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res. 2007;9:R14.
32. Gooz P, Gooz M, Baldys A, Hoffman S. ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. Biochem Biophys Res Commun. 2009;380:33-38.
33. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, Hinoki A, Eguchi S, Guaiquil V, Horiuchi K, Blobel CP. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res. 2010;106:932-940.
34. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004;64:5535-5538. (Pubitemid 39095544)
35. Fainaru O, Adini A, Benny O, Adini I, Short S, Bazinet L, Nakai K, Pravda E, Hornstein MD, D'Amato RJ, Folkman J. Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis. FASEB J. 2008;22:522-529. (Pubitemid 351225588)
36. Ferrero E, Vettoretto K, Bondanza A, Villa A, Resnati M, Poggi A, Zocchi MR. uPA/uPAR system is active in immature dendritic cells derived from CD14 + CD34+ precursors and is down-regulated upon maturation. J Immunol. 2000;164:712-718. (Pubitemid 30043692)
37. Brown J, Jones EY, Forbes BE. Interactions of IGF-II with the IGF2R/ cation-independent mannose-6-phosphate receptor mechanism and biological outcomes. Vitam Horm. 2009;80:699-719.
38. El-Shewy HM, Luttrell LM. Insulin-like growth factor-2/mannose-6 phosphate receptors. Vitam Horm. 2009;80:667-697.
39. Valenzano KJ, Remmler J, Lobel P. Soluble insulin-like growth factor II/mannose 6-phosphate receptor carries multiple high molecular weight forms of insulin-like growth factor II in fetal bovine serum. J Biol Chem. 1995;270:16441-16448.
40. Duplomb L, Chaigne-Delalande B, Vusio P, Raher S, Jacques Y, Godard A, Blanchard F. Soluble mannose 6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibits interleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II. Endocrinology. 2003;144:5381-5389. (Pubitemid 37476067)
41. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res. 2006;66: 1940-1948.
42. Zaina S, Squire S. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms. J Biol Chem. 1998;273:28610-28616. (Pubitemid 28507544)
43. Lorenzo K, Ton P, Clark JL, Coulibaly S, MachL. Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate/ insulin-like growth factor II receptor. Cancer Res. 2000;60:4070-4076. (Pubitemid 30636587)
44. Kovacina KS, Steele-Perkins G, Purchio AF, Lioubin M, Miyazono K, Heldin CH, Roth RA. Interactions of recombinant and platelet transforming growth factor-beta 1 precursor with the insulin-like growth factor II/mannose 6-phosphate receptor. Biochem Biophys Res Commun. 1989; 160:393-403. (Pubitemid 19116510)
45. Wood RJ, Hulett MD. Cell surface-expressed cation-independent mannose 6-phosphate receptor (CD222) binds enzymatically active hepa-ranase independently of mannose 6-phosphate to promote extracellular matrix degradation. J Biol Chem. 2008;283:4165-4176.
46. Blanchard F, Raher S, Duplomb L, Vusio P, Pitard V, Taupin JL, Moreau JF, Hoflack B, Minvielle S, Jacques Y, Godard A. The mannose 6-phosphate/insulin- like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor. J Biol Chem. 1998;273:20886-20893. (Pubitemid 28385368)
47. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007;97: 336-342. (Pubitemid 46437793)
48. Tahiri K, Cam L, Desbuquois B, Chauvet G. Processing of the insulin-like growth factor-II-mannose 6-phosphate receptor in isolated liver subcellular fractions. Biochem Cell Biol. 2001;79:469-477. (Pubitemid 32744982)
49. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res. 2006;312:608-622. (Pubitemid 43290337)
50. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6:32-43. (Pubitemid 40064897)
51. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15: 1140-1144.
52. Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y, Blobel CP. Cutting edge: TNF-alpha-converting enzyme (TACE/ ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol. 2007;179:2686-2689.
53. Jones AL, Hulett MD, Altin JG, Hogg P, Parish CR. Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. J Biol Chem. 2004;279:38267-38276. (Pubitemid 39295974)
54. Weinstein MJ, Doolittle RF. Differential specificities of the thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors. Biochim Biophys Acta. 1972;258:577-590.
55. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastro-enterol. 2009;104:96-101.
56. Tripodi A, Primignani M, Chantarangkul V, Dell'era A, Clerici M, de Franchis R, Colombo M, Mannucci PM. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroen-terology. 2009;137:2105-2111.
57. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009;9:81-94.